Tyrosine-kinase inhibitors in the treatment of non-small cell lung cancer in usual clinical practice

被引：0
|
作者：
Caparros Romero, S. [1 ]
Ruiz Fuentes, S. [1 ]
机构：
[1] Hosp Axarquia, Pharm, Malaga, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2022年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PP176
引用
收藏
页码：1553 / 1553
页数：1
相关论文
共 50 条
  • [31] Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
    Gao, Yuan
    Song, PingPing
    Li, Hui
    Guo, HongBo
    Jia, Hui
    Zhang, BaiJiang
    ONCOTARGETS AND THERAPY, 2016, 9 : 13 - 20
  • [32] Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients
    Viteri, Santiago
    Rosell, Rafael
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S643 - S646
  • [33] Treatment of Non-Small Cell Lung Cancer Patients in the Intensive Care Units with EGFR-Tyrosine Kinase Inhibitors
    Lee, I.
    Yang, C.
    Shih, J.
    Yu, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [34] Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer
    Yang, Lili
    Liu, Shanshan
    Chu, Jingjing
    Miao, Shuang
    Wang, Kai
    Zhang, Qingwei
    Wang, Yingyi
    Xiao, Yadi
    Wu, Lina
    Liu, Yang
    Yu, Longjian
    Yu, Caihong
    Liu, Xiang
    Ke, Mingxing
    Cheng, Zhen
    Sun, Xilin
    BIOMATERIALS SCIENCE, 2021, 9 (02) : 443 - 455
  • [35] The Radiosensitivity of Tyrosine Kinase Driven Non-small Cell Lung Cancer
    Johung, K. L.
    Yu, J. B.
    Gettinger, S. N.
    Decker, R. H.
    Hess, J. A.
    Chiang, V. L.
    Contessa, J. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S115 - S115
  • [36] Receptor tyrosine kinase mutations in non-small cell lung cancer
    Hayashi, H.
    Togashi, Y.
    Terashima, M.
    Sakai, K.
    Mizuuchi, H.
    Kobayashi, Y.
    Suda, K.
    Nakagawa, K.
    Nishio, K.
    Mitsudomi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S601 - S601
  • [37] Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic
    Skrickova, Jana
    Chloupkova, Renata
    Bortlicek, Zbynek
    Brabec, Petr
    Hejduk, Karel
    Dusek, Ladislav
    Pesek, Milos
    Kolek, ViTezslav
    Koubkova, Leona
    Cernovska, Marketa
    Salajka, Frantisek
    Zemanova, Milada
    Krejci, Jana
    Coupkova, Helena
    Satankova, Monika
    Benejova, Andrea
    Tomiskova, Marcela
    Roubec, Jaromir
    Grygarkova, Ivona
    Havel, Libor
    Hrnciarik, Michal
    Opalka, Petr
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [38] Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer
    Fasano, Morena
    Della Corte, Carminia Maria
    Califano, Raffaele
    Capuano, Annalisa
    Troiani, Teresa
    Martinelli, Erika
    Ciardiello, Fortunato
    Morgillo, Floriana
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (06) : 809 - 821
  • [39] Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment
    Rajappa, Senthil
    Krishna, M. Vamshi
    Narayanan, Prasad
    ADVANCES IN THERAPY, 2019, 36 (06) : 1279 - 1290
  • [40] Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment
    Senthil Rajappa
    M. Vamshi Krishna
    Prasad Narayanan
    Advances in Therapy, 2019, 36 : 1279 - 1290
12345